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Pelvic inﬂammatory disease (PID) is a frequent condition of young women, often resulting in reproductive morbidity. Although
Neisseria gonorrhoeae and/or Chlamydia trachomatis are/is recovered from approximately a third to a half of women with PID, the
etiologicagentisoftenunidentiﬁed.WeneedPCRtotestforMgenitaliumamongapilotsampleof50womenwithnongonococcal,
nonchlamydial endometritis enrolled in the PID evaluation and clinical health (PEACH) study. All participants had pelvic pain,
pelvic organ tenderness, and leukorrhea, mucopurulent cervicitis, or untreated cervicitis. Endometritis was deﬁned as ≥5s u r f a c e
epithelium neutrophils per ×400 ﬁeld absent of menstrual endometrium and/or ≥2 stromal plasma cells per ×120 ﬁeld. We
detected M genitalium in 7 (14%) of the women tested: 6 (12%) in cervical specimens and 4 (8%) in endometrial specimens. We
conclude that M genitalium is prevalent in the endometrium of women with nongonococcal, nonchlamydial PID.
Copyright © 2006 Catherine L. Haggerty et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Mycoplasma genitalium was ﬁrst identiﬁed in the early 1980s
among men with nongonococcal urethritis [1]. M genital-
ium is extremely diﬃcult to culture, but the use of poly-
merase chain reaction (PCR) technology has allowed re-
search into the pathogenicity of this organism. Numerous
studies have conﬁrmed the role of M genitalium in drug re-
sistant nongonococcal urethritis [2–18], and four relatively
recentstudieshaveshownMgenitaliumtobeassociatedwith
cervicits[19–22],independentofChlamydiatrachomatisand
Neisseria gonorrhoeae [20–22]. Few studies have examined
M genitalium among women with pelvic inﬂammatory dis-
ease (PID), the common infection and inﬂammation of the
female upper genital tract which may lead to major repro-
ductive morbidity including infertility, chronic pelvic pain,
ectopic pregnancy, and recurrent PID [23]. Whereas sero-
logical studies of M genitalium and PID among women have
been suggestive but inconclusive [24, 25], PCR studies have
associated M genitalium with clinically suspected PID [19–
26] and acute endometritis [27]. Only one of these studies
conﬁrmed the diagnosis of PID histologically [27], and no
studies have examined M genitalium among a population of
US women with PID.
Ct r a c h o m a t i sand/or N gonorrhoeae account for approx-
imately a third to half of PID cases [30, 32–36, 38–50]. Thus,
since up to 70% of PID cases have a largely unidentiﬁed eti-
ology, the discovery of new pathogens associated with up-
per genital tract infection in women would be informative.
Anaerobic gram-negative rods and bacterial vaginosis have
been associated with PID [30–32, 36–38, 43, 45–50], and we
have recently shown this association to be independent of
gonococcal and chlamydial infection [51]. It is feasible that
M genitalium may also be an etiologic agent in nongonococ-
cal, nonchlamydial PID, as it has been found to induce salp-
ingitis experimentally in monkeys [52, 53], has been shown
to adhere to human fallopian tube epithelial cells in organ
culture [54], and has been detected in fallopian tube tissue
in a woman with salpingitis [55]. Further, M genitalium has
been shown to adhere to human spermatozoa, and therefore
may potentially be carried by motile sperm to the female up-
per genital tract [56].
SUBJECTS
We conducted a pilot substudy to determine the preva-
lence of M genitalium among a sample of urban US women
with nongonococcal, nonchlamydial PID using specimens2 Infectious Diseases in Obstetrics and Gynecology
collected as part of the PID evaluation and clinical health
(PEACH) study. The methods of PEACH study participant
recruitment, data collection, and followup have been de-
scribed in detail elsewhere [57]. Brieﬂy, women aged 14 to 37
years were recruited from emergency departments, OB/GYN
clinics, STD clinics, and private practices at thirteen clini-
cal sites located throughout the eastern, southern, and cen-
tral regions of the US between March 1996 and February
1999. Women with clinically suspected PID who gave in-
formed consent were eligible for the PEACH study. All par-
ticipants had clinically suspected PID: pelvic, pain, pelvic or-
gan tenderness; and leukorrhea, mucopurulent cervicitis, or
untreated cervicitis. Eight hundred thirty one women met all
of the inclusion criteria and were enrolled into the PEACH
study. Six hundred ﬁfty four women consented to endome-
trial biopsies. Histologic evidence of endometritis, deﬁned as
≥ 5 surface epithelium neutrophils per ×400 ﬁeld absent of
menstrual endometrium and/or ≥ 2 stromal plasma cells per
×120 ﬁeld, was found among 311 women.
METHODS
Cervical and endometrial specimens from a sample of 50
women with nongonococcal, nonchlamydial endometritis
were tested for M genitalium using the MgPa-IMW PCR as-
say targeting the MgPa gene [19]. For all samples testing pos-
itive for M genitalium, a second MgPa PCR assay was per-
formed using another aliquot of the sample to rule out PCR
product contamination or cross-contamination; all samples
initially positive were veriﬁed as positive in this conﬁrmatory
test. Frequencies and Pearson’s correlations were calculated
using SAS version 8.2 for Windows.
RESULTS
We detected M genitalium in 7 (14%) of the women tested.
Twelve percent of cervical specimens and 8 percent of en-
dometrial specimens were positive for M genitalium, and in-
fection at these sites was highly correlated (Pearson’s corre-
lation 0.57, p = 0.0001), with 75% of endometrial positive
cases also positive at the cervix and 50% of cervical posi-
tivecasesalsopositiveintheendometrium.Bothplasmacells
and neutrophils were identiﬁed in 3 (75%) of the 4 women
with endometrial M genitalium compared to 18 (42%) of 43
women without M genitalium in the endometrium, although
these ﬁndings were not statistically signiﬁcant.
DISCUSSION
We identiﬁed M genitalium frequently among an urban US
population of women with nongonococcal, nonchlamydial
PID. The overall prevalence of 14% is similar to that found
in prior PCR investigations among Kenyan women with his-
tologically conﬁrmed endometritis (16%) [27] and United
Kingdom women with clinically suspected PID (13%) [26].
In the PEACH study, about 14% of women were infected
with Ct r a c h o m a t i s , 15% were infected with N gonorrhoeae,
and 5% were coinfected [58]. Thus, M genitalium was as
prevalent as Ctr achomatisor Ngonorrhoeae among this pop-
ulation of women with PID.
Most women with PID are treated with antibiotics di-
rected toward N gonorrhoeae and/or Ct r a c h o m a t i s , despite
the fact that these bacterial pathogens account for only a
third to half of PID cases. Indeed, in the PEACH study the
majority of women, approximately 60%, had nongonococ-
cal, nonchlamydial PID [58]. Over a third of the women in
the PEACH study had persistent endometritis at 30 days [58]
and over a third experienced chronic pelvic pain subsequent
to baseline [59], suggesting that a sizeable portion of women
in the PEACH study had ongoing inﬂammation and infec-
tion. Women in the PEACH study were treated with a com-
bination of cefoxitin and doxycycline [58], a PID treatment
regimen currently recommended by the centers for disease
control and prevention. No studies have examined the eﬃ-
cacy of this or any other treatment regimen among women
withMgenitaliumPID.However,severalattributesofMgen-
italium suggest it is resistant to cefoxitin and doxycycline.
First, mycoplasmal bacteria lack a cell wall, and are thus re-
sistant to cell wall inhibiting antibiotics, including penicillin
and cephalosporin. Second, M genitalium has been found to
persist among men treated with tetracyclines for nongono-
coccal urethritis [60]. Antibiotic resistance among Mg e n i -
talium strains may lead to persistent or recurrent infection
among women with PID, resulting in chronic inﬂammation




Successful treatment of PID is critical for the preven-
tion of subsequent reproductive morbidity. We have previ-
ously shown that women in the PEACH study with N gonor-
rhoeae or Ct r a c h o m a t i sidentiﬁed in the endometrium were
not more likely to experience infertility, chronic pelvic pain,
or recurrent PID than those negative for each [59]. Fur-
ther, those who tested positive for nongonococcal bacteria
were generally more likely to experience reproductive mor-
bidity than were women with endometrial gonococcal infec-
tion (infertility rates were 13% for N gonorrhoeae, 19% for
Ct r a c h o m a t i s , 22% for anaerobic bacteria, 27% for Uu r e -
alyticum, and 17% for M hominis; chronic pelvic pain rates
were 27% for N gonorrhoeae, 21% for Ctr a c h o m a ti s , 33% for
anaerobic bacteria, 41% for Uu r e a l y t i c u m , and 54% for M
hominis). Thus, women with nongonococcal PID may be at
greaterriskforadverseoutcomes.Fewstudieshaveexamined
reproductive sequelae attributed to M genitalium upper gen-
ital tract infection, but M genitalium antibodies have been
identiﬁed more frequently (22% versus 6%) among women
with tubal factor infertility compared to women with non-
tubal factor infertility [61].
Given the frequency of M genitalium among women with
PID demonstrated in this report and in those by previous in-
vestigators [19, 26, 27], we recommend that treatment for
P I Db er e e v a l u a t e df o ri t se ﬀectiveness against nongonococ-
cal, nonchlamydial PID. M genitalium has demonstrated sus-
ceptibility to macrolides, with azithromycin being the most
active, and variable resistance to ﬂuroquinolones, includingCatherine L. Haggerty et al 3
ciproﬂoxacin [60, 62]. A newer quinolone, moxiﬂocacin, has
recently been shown to exhibit better activity against Mg e n -
italium [63]. Further study of alternative regimens for the
treatmentofMgenitaliumPID and the prevention of adverse
reproductive sequelae is needed.
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